Thyrotropin secretion in patients with central hypothyroidism: Evidence for reduced biological activity of immunoreactive thyrotropin
Abstract
TSH concentration was measured in plasma before and after TRH administration (200 micrograms, iv) in 89 patients with documented hypothyroidism consequent to various hypothalamic-pituitary disorders. Basal plasma TSH was less than 1.0 microI/ml in 34.8%, between 1.0-3.6 microU/ml in 40.5% and slightly elevated (3.7-9.7 microU/ml) in 24.7% of the cases. The plasma TSH response to TRH was absent in 13.5%, impaired in 16.8%, normal in 47.2%, and exaggerated in 22.5% of the cases, with delayed and/or prolonged pattern of response in 65% of the cases. The dilution curves of several plasmas drawn before and after TRH were parallel to those obtained with TSH standard preparation. After gel filtration, the elution pattern of TRH-stimulated plasmas from 4 patients did not show any major difference from that of pooled plasmas from normal subjects given TRH or from that of patients with primary hypothyroidism. Plasma TSH values determined by cytochemical bioassay on both basal and TRH-stimulated samples of 5 patients were markedly lower than those obtained by RIA. The serum T3 response to TRH was absent or low in 40 out of 53 patients in whom it was evaluated. The administration of T3 (100 micrograms/day for 3 days) or dexamethasone (3 mg/day for 5 days) respectively suppressed or reduced both basal and TRH-induced plasma TSH levels. Two patients became hypothyroid shortly after pituitary surgery in spite of basal and TRH-induced plasma TSH levels similar to or higher than those before surgery. Though thyroid atrophy due to chronic understimulation could explain the low T3 response to TRH in secondary hypothyroidism, it is difficult to reconcile thyroid understimulation with normal or increased plasma TSH unless the immunoreactive material has low biological activity. Present data suggest that several patients with hypothyroidism consequent to hypothalamic-pituitary diseases secrete a material which is immunologically similar to pituitary standard TSH and responds to stimulatory and suppressive agents in a manner similar to normal TSH but has low or absent biological activity. Thus, hypothyroidism due to insufficient TSH stimulation can be termed central hypothyroidism and can be due 1) to pituitary insufficiency (secondary hypothyroidism), 2) to a hypothalamic defect (tertiary hypothyroidism), or 3) to the secretion of biologically inactive TSH.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The proposed mechanism for disproportionately high TSH in central hypothyroidism involves abnormal glycosylation of the TSH alpha and beta subunits, rendering the secreted TSH biologically inactive.
“The proposed mechanism for disproportionately high TSH in central hypothyroidism involves abnormal glycosylation of the TSH alpha and beta subunits, rendering the secreted TSH biologically inactive [55,56].”
From Endocrine Dysfunctions After Pediatric Traumatic Brain Injury: Present Insights and Future Directions (2025) · cites this paper as [55]
The suggested mechanism for central hypothyroidism with elevated TSH is abnormal glycosylation of TSH alpha and beta subunits, so secreted TSH is not biologically active.
“The suggested mechanism for central hypothyroidism with elevated TSH is abnormal glycosylation of the TSH alpha and beta subunits, thus the TSH secreted is not biologically active [67,68].”
From Update of Endocrine Dysfunction following Pediatric Traumatic Brain Injury (2015) · cites this paper as [67]
Poor intrinsic biological activity of secreted TSH molecules is a pathological mechanism accounting for central hypothyroidism.
“(c) poor intrinsic biological activity of secreted TSH molecules [14-18].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [14]
In central hypothyroidism patients with high immunoreactive TSH, TSH elevations are similar to those generally found in subclinical or mild primary hypothyroidism and may lead to misdiagnosis.
“In these cases, TSH elevations are similar to those generally found in subclinical or mild primary hypothyroidism and may lead to misdiagnosis [14-17, 30, 42].”
From 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism (2018) · cites this paper as [14]
In this subgroup, TSH levels are superimposable to those generally found in subclinical or mild primary hypothyroidism, although the molecule is devoid of full biological activity and FT4 is already in the hypothyroid range.
“In this subgroup of patients, TSH levels are superimposable to those generally found in subclinical or mild primary hypothyroidism, although the molecule is devoid of full biological activity and the FT4 is already in the hypothyroid range (13, 14, 16, 17).”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [13]
The citation lists haven’t been fetched yet
References 30 · Cited by 197
- Authors
- FAGLIA, G., BITENSKY, L., PINCHERA, A., FERRARI, C., PARACCHI, A., BECK-PECCOZ, P., AMBROSI, B., & SPADA, A.
- Affiliations
- University of Pisa (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- ORCID
- FERRARI, CARLO
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1979-06
- Volume
- 48
- Issue
- 6
- Pages
- 989-998
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1978874398
- Cited by
- 197
- References
- 30
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 4
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- central hypothyroidism, thyroid-stimulating hormone, TSH receptor, thyrotropin-releasing hormone, dexamethasone, hypothalamic-pituitary dysfunction, pituitary surgery, thyroid atrophy
- MeSH terms
- Biological Assay, Brain Neoplasms, Dexamethasone, Humans, Hypothalamus, Hypothyroidism, Pituitary Neoplasms, Thyrotropin, Thyrotropin-Releasing Hormone, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review